Core Viewpoint - Extrovis AG and Dr. Reddy's Laboratories have launched an authorized generic version of CARAC (fluorouracil cream), 0.5%, in the U.S. market, which is expected to enhance patient access to this treatment [2][4]. Group 1: Product Launch - The authorized generic Fluorouracil Cream, 0.5%, is approved by the U.S. Food and Drug Administration (USFDA) and is manufactured in Texas [2][3]. - This product is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp [3][6]. Group 2: Strategic Partnership - The collaboration between Extrovis AG and Dr. Reddy's aims to increase patient access and create long-term value for the U.S. healthcare system [4][5]. - Dr. Reddy's expertise in commercialization and distribution within the U.S. market is highlighted as a key asset in this partnership [5]. Group 3: Company Background - Extrovis AG is a global biopharmaceutical company focused on developing high-quality therapies for unmet medical needs, with R&D and manufacturing operations in multiple countries [9]. - Dr. Reddy's Laboratories, established in 1984, is committed to providing access to affordable and innovative medicines across various therapeutic areas, including oncology and dermatology [8].